Pelareorep - Oncolytics Biotech

Drug Profile

Pelareorep - Oncolytics Biotech

Alternative Names: PO-BB0209; REOLYSIN; Reosyn; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncolytics Biotech
  • Developer Mayo Clinic; National Cancer Institute (Canada); National Cancer Institute (USA); Oncolytics Biotech; University of Leeds; University of Southern California
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fallopian tube cancer; Glioma; Peritoneal cancer; Ovarian cancer; Gastric cancer; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • Phase II Brain cancer; Breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
  • Phase I/II Glioma
  • Phase I Multiple myeloma
  • Preclinical Hepatocellular carcinoma; Viral hepatitis
  • No development reported Solid tumours

Most Recent Events

  • 14 Dec 2017 Oncolytics Biotech plans to submit aaplication for Breakthrough therapy designation to US FDA for Breast cancer in Q1-2018
  • 14 Dec 2017 Oncolytics Biotech plans to submit special protocol assessment for a phase III trial in Breast cancer (Metastatic disease) in Q1-2018
  • 14 Dec 2017 Oncolytics Biotech plans a phase III registrational study for Breast cancer (Metastatic disease, Second-line therapy or greater) in Europe and USA in Q3-2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top